Pharmaceutical research and development funding is notoriously costly and faces ever-increasing challenges on a number of fronts: regulatory hurdles, increasing uncertainty in patent protection, and loss of consumer confidence stemming from recent studies undermining the previously-claimed benefits of established drugs.

The current trend towards development of niche pharmaceutical products, sometimes crossing over into biotechnology, brings pharmaceutical development into the potential purview of firms of more modest means than the traditional developers of blockbuster drugs. Research funding can potentially be drawn from the SR&ED and/or IRAP programs, as well as a range of other programs, dependent on the details of the research work undertaken or proposed and how it meshes with the criteria of each.

The nature of pharmaceutical research and development is likely to involve a high degree of classical experimentation and analysis, one of the criteria of the SR&ED program. However, it is also critical to appropriately scope the boundaries of the R&D project to properly claim the project and its associated technological advances for R&D funding purposes.

TSGI can assist with evaluating your company’s past, current, and proposed research work against all of the criteria of the SR&ED and other research and development funding programs, and with scoping and submitting successful tax credit and/or grant funding proposals for pharmaceuticals.